WA-KARAT
13.10.2021 14:02:12 CEST | Business Wire | Press release
Karat , the world leader in technical interviewing and pioneer of the Interviewing Cloud , today announced a $110 million Series C funding round at a $1.1 billion valuation. Karat’s industry-defining human + technology solution delivers live technical interviews on behalf of clients 24/7 while forging deep strategic partnerships that unlock enormous value for engineering and talent acquisition leaders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005399/en/
Software engineers are the lifeblood of the modern organization, and the gap between the supply of talent and demand will continue to widen in the coming decades. In the race to hire, companies are investing $60 billion a year of engineering time spent interviewing. Yet, despite that investment, most organizations don’t have enough bandwidth to interview at the necessary scale and velocity to compete for top talent. Furthermore, the time that is being invested is ineffective as do-it-yourself interviews fail to create a structured, consistent, and candidate-centric hiring process.
“Just like the public cloud moved everyone from private computing to shared infrastructure, Karat’s Interviewing Cloud is upending the old way of do-it-yourself interviewing that eats into valuable engineering time and fails to delight candidates,” said Mohit Bhende, Karat co-founder and CEO. “By professionalizing interviewing and developing purpose-built interviewing technology, Karat enables companies to innovate faster and candidates to showcase their strengths in a comfortable environment.”
The twofold benefit of reclaiming engineering time and accelerating technical hiring is driving massive adoption of the Interviewing Cloud. Karat has tripled bookings and doubled its number of customers over the past year. In addition to the rapid growth, Karat continues to deepen its partnerships, with the average enterprise client doubling their contract size year-over-year, including eight companies now spending more than $1M per year.
“Karat’s Interviewing Cloud has been a game-changer for us. We’ve gotten back over 25,000 hours of developer time that we’re able to spend innovating and building products," said Joseph Sirosh, CTO at Compass. "Our candidates love the Karat experience and they move more quickly through the process. Without Karat, it would have been a challenge to grow our engineering team at the pace that we have, and with the high talent bar that we have.”
Karat’s impressive growth and market opportunity motivated inside-investors, including Norwest Venture Partners, 8VC, Exor, Base Partners, and Sempervirens Fund, to join Tiger Global in expanding their investments. Collectively, these investors account for 99% of the latest capital raise.
"We believe Karat’s human + technology Interviewing Cloud is the way most companies will hire engineers,” said Scott Shleifer, partner at Tiger Global. “We know the gap between the supply of engineering talent and demand will continue to widen and are excited to deepen our investment in the category creator and leader."
The new capital will allow Karat to rapidly scale its global infrastructure and go-to-market function to accelerate growth. Karat is also investing heavily in data science and interview innovation to unlock insights for companies and accelerate hiring processes for candidates. Karat’s market intelligence will deliver unparalleled benchmarking insights driven by the world’s largest cross-company interview dataset.
“Karat’s Interviewing Cloud has become a significant differentiator for how we hire engineers,” said Jonathan Kehoe, Director of Talent at Wayfair. “Karat is incredibly consistent and has data nobody else has, it’s like holding a mirror up to your full hiring process and seeing what’s working well and where you need to improve.”
The expertise and data generated from hundreds of thousands of interviews also allows Karat to create more candidate-centric experiences, particularly for software engineers who have been previously overlooked by traditional hiring practices.
“Innovations like the redo, candidate feedback and our Brilliant Black Minds program are giving candidates from nontraditional backgrounds more opportunities to break into tech and are creating more equitable hiring processes,” said Jeffrey Spector, Karat co-founder and President. “As we launch Karat’s next chapter of growth, delivering fair and inclusive candidate experiences continues to be our North Star.”
To learn more about Karat, visit karat.com .
About Karat
Karat created the world’s first Interviewing Cloud to solve the multi-decade global shortage of software engineers. The Interviewing Cloud is an always-on, scalable, and consistent human + technology solution for conducting predictive, fair, and enjoyable technical interviews 24/7. Karat’s global network of Interview Engineers, unparalleled market intelligence, and purpose-built interviewing infrastructure opens the pipeline for engineering talent, limits pedigree bias, and provides access for underrepresented candidates. The fastest growing and largest enterprises such as Roblox, American Express, Intuit, Compass, and Wayfair trust Karat to expand hiring capacity, unlock developer time, and raise engineering quality so they can innovate and grow. For more information, please visit: www.karat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005399/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
